LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. today announced the completion of the third planned safety review of patients enrolled in Cubist's ongoing international Phase 3 clinical trial examining the safety and efficacy of Cubicin (daptomycin for injection) in the treatment of infective endocarditis and bacteremia caused by Staphylococcus aureus. This is the first Phase 3 trial to be conducted for the indication of endocarditis in almost 20 years.
Due to the high mortality rate associated with endocarditis, blinded clinical data from patients enrolled in the study are provided to an independent data monitoring committee (DMC) at pre-determined intervals to identify any safety-related issues. Based upon this review of data from more than 100 treated patients, the DMC has recommended continuation of the trial.
Patients with blood cultures positive for the presence of S. aureus are currently being enrolled at sites in the U.S. and certain Western European countries. The study has recently been expanded to include patients with left-sided endocarditis. Previously the protocol included patients with right-sided endocarditis and complicated or uncomplicated bacteremia. In the study, patients receive either Cubicin, at 6 mg/kg once daily, or the current standards of care, vancomycin in patients with confirmed methicillin-resistant S. aureus (MRSA) infection or a semi-synthetic penicillin if susceptible S. aureus is confirmed. Cubist continues to expect data from the trial to be available in the first half of 2005.
Cubicin is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of certain Gram-positive microorganisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cubicin, it should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria susceptible to Cubicin.
Source: Cubist Pharmaceuticals, Inc.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.